已收录 268921 条政策
 政策提纲
  • 暂无提纲
Biomaterials for vaccine-based cancer immunotherapy
[摘要] The development of therapeutic cancer vaccines as a means to generate immune reactivity against tumors has been explored since the early discovery of tumor-specific antigens by Georg Klein in the 1960s. However, challenges including weak immunogenicity, systemic toxicity, and off-target effects of cancer vaccines remain as barriers to their broad clinical translation. Advances in the design and implementation of biomaterials are now enabling enhanced efficacy and reduced toxicity of cancer vaccines by controlling the presentation and release of vaccine components to immune cells and their microenvironment. Here, we discuss the rational design and clinical status of several classes of cancer vaccines (including DNA, mRNA, peptide/protein, and cell-based vaccines) along with novel biomaterial-based delivery technologies that improve their safety and efficacy. Further, strategies for designing new platforms for personalized cancer vaccines are also considered.
[发布日期] 2018-12-28 [发布机构] 
[效力级别]  [学科分类] 
[关键词] Cancer vaccine;Immunotherapy;Biomaterials;Targeted delivery;Personalized therapy;Translational research;Nanomedicine;Nucleic acid delivery [时效性] 
   浏览次数:8      统一登录查看全文      激活码登录查看全文